Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202444 | 0.76 | CPT2 (0.40) | PGK1PGK2LMNA | |
| Phosphoric Acid SCHEMBL5917774 | 0.74 | KDM4E (0.33) | PGK1PGK2KDM4ETSHRTDP1 | |
| SCHEMBL8842579 | 0.71 | LMNA (0.36) | LMNATSHR | |
| Alcohol SCHEMBL11401577 | 0.69 | FDPS (0.33) | PGK1PGK2LMNA | |
| SCHEMBL19043014 | 0.67 | FOLH1 (0.36) | LMNATSHRTDP1 | |
| SCHEMBL29136874 | 0.67 | PGK1 (0.33) | PGK1PGK2LMNA | |
| SCHEMBL28420318 | 0.64 | LMNA (0.35) | PGK1PGK2LMNATSHRTDP1 | |
| SCHEMBL28920015 | 0.64 | KDM4E (0.39) | PGK1PGK2LMNAKDM4ETSHR | |
| SCHEMBL8895794 | 0.62 | LMNA (0.40) | PGK1PGK2LMNATSHRTDP1 | |
| SCHEMBL15707796 | 0.62 | LMNA (0.40) | PGK1PGK2LMNATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-4438734-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | PROPANC PTY LTD (AU) | 2023-05-04 | — | — | US | disclosed |
| US-20220280460-A1 | METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-09-08 | — | — | US | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| WO-2021040999-A1 | METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2006-02-02 | — | — | US | disclosed |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6670330-B1 | Treating human breast cancer | LAMPIDIS THEODORE J (US) | 2003-12-30 | — | — | US | disclosed |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | PGK1 58/4885PGK2 133/4885LMNA 4786/4885 |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | PGK1 22/4885PGK2 40/4885LMNA 4687/4885 |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | PGK1 22/4885PGK2 40/4885LMNA 4687/4885 |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | PGK1 22/4885PGK2 40/4885LMNA 4687/4885 |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | SPINT2, PRSS1, SERPINB1 | PGK1 109/4885PGK2 153/4885LMNA 3077/4885 |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | PGK1 502/4885PGK2 514/4885LMNA 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.